Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

LEE011

Base Information Edit
LEE011

Synonyms:LEE011;LEE 011;LEE-011;

Suppliers and Price of LEE011
Supply Marketing:Edit
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
  • TRC
  • CDK4/6Inhibitor
  • 25mg
  • $ 1470.00
  • Matrix Scientific
  • 4-(5-Chloro-3-isopropyl-1H-pyrazol-4-yl)-N-(5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)pyrimidin-2-amine 95%
  • 250mg
  • $ 740.00
  • Matrix Scientific
  • 4-(5-Chloro-3-isopropyl-1H-pyrazol-4-yl)-N-(5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)pyrimidin-2-amine 95%
  • 1g
  • $ 1656.00
  • Biorbyt Ltd
  • Ribociclib (LEE011) >99%
  • 1 g
  • $ 1802.00
  • Biorbyt Ltd
  • Ribociclib (LEE011) >99%
  • 250 mg
  • $ 912.90
  • Biorbyt Ltd
  • Ribociclib (LEE011) >99%
  • 100 mg
  • $ 606.90
  • Biorbyt Ltd
  • Ribociclib >98%
  • 50 mg
  • $ 430.10
  • Biorbyt Ltd
  • Ribociclib >98%
  • 10 mg
  • $ 190.40
Total 55 raw suppliers
Chemical Property of LEE011 Edit
Chemical Property:
  • Boiling Point:679.3±65.0 °C(Predicted) 
  • PKA:7.57±0.50(Predicted) 
  • PSA:85.86000 
  • Density:1.31±0.1 g/cm3(Predicted) 
  • LogP:4.45050 
  • Storage Temp.:-20°C Freezer 
  • Solubility.:DMSO (Slightly), Methanol (Slightly) 
Purity/Quality:

99% *data from raw suppliers

CDK4/6Inhibitor *data from reagent suppliers

Safty Information:
  • Pictogram(s):  
  • Hazard Codes: 
MSDS Files:

SDS file from LookChem

Useful:
  • Description LEE011 (also known as ribociclib) is a CDK4/6 inhibitor. It has been recently approved by FDA (brand name: Kisqali?) to be combined with an aromatase inhibitor for initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. It inhibits the growth of tumor cells by arresting the cells at the G1 checkpoint, which prevents the tumor cells from proliferating. In the phase III trial, it demonstrating statistically significant improvement in progression-free survival (PFS) compared to letrozole alone at the first pre-planned interim analysis.
  • Uses CDK 4/6 Inhibitor is a part of a group of compounds that exhibits selective inhibitory properties towards Cyclin-Dependent Kinases 4 & 6. These compounds are most commonly used to treat patients with breast cancer.
Post RFQ for Price